WASHINGTON, DC (January 22, 2019)— The Association for Accessible Medicines (AAM) is pleased to announce that three new members have joined its Biosimilars Council:
- Accord Healthcare Inc.
- Fresenius Kabi USA, LLC
- Sagent Pharmaceuticals, Inc.
FDA-approved biosimilars have been estimated to have the potential to save patients and the health care system anywhere from $54 to $250 billion over their first 10 years on the market. Indeed, although the U.S. biosimilars market is still in its nascency, currently marketed biosimilars are competitively priced 40 percent lower on average than their brand reference products in terms of list price.
A complete list of Biosimilars Council Members can be found here.